Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma

Raimonda Kubiliute1 Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania;2 National Cancer Institute, Vilnius, LithuaniaView further author information

Algirdas Zalimas1 Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania;2 National Cancer Institute, Vilnius, LithuaniaView further author information

Arnas Bakavicius2 National Cancer Institute, Vilnius, Lithuania;3 Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania;4 Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaView further author information

Albertas Ulys2 National Cancer Institute, Vilnius, LithuaniaView further author information

Feliksas Jankevicius3 Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania;4 Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaView further author information

Sonata Jarmalaite1 Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania;2 National Cancer Institute, Vilnius, LithuaniaCorrespondence[email protected]
View further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date